Regeneron Pharmaceuticals, Inc. (REGN) Prepares for $83M Charge

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the top stocks to buy in Michael Burry’s stock portfolio. On October 6, the company announced it is poised to incur an $83 million in-process research and development (IPR&D) charge.

The charge is related to an $80 million up-front payment made to Hansoh Pharmaceuticals Group Company Limited as part of a 2025 license agreement. In addition to up-front, opt-in, and some development milestone payments, acquired IPR&D charges may also include milestone payments and premiums paid on equity securities associated with licensing and partnership agreements.

The charge is expected to reduce the company’s GAAP and non-GAAP net income per diluted share by about $0.68 in the third quarter.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology company that discovers, develops, manufactures, and commercializes medicines for serious and rare diseases, including eye diseases, cancer, neurological conditions, inflammatory and allergic diseases, and cardiovascular diseases.

While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Top 10 Materials Stocks to Buy According to Analysts and 10 Best Organic Food and Farming Stocks to Buy Now.

Disclosure: None. This article is originally published at Insider Monkey.